Market Cap
$1.7B
ANIP
ANI PHARMACEUTICALS INC
$71.85 ▼ -1.53%
Prev close $72.96Market cap$1.7B
ConsensusStrong Buy
12-mo target$105.78 (+47.2%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)26 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ANIP right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$1.3B
Inst. Activity
26 buys / 17 sells
Insider Activity
$0.00 buy / $10.7M sell
Insider Net $
-$10.7M
Social Sentiment
50° Neutral
SEC Reports
18
Press Releases
3
Price chart 30d -1.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 Insider
CAREY STEPHEN P. sold 2,850 shares
SVP & CFO @ $73.00 ($208.1K)
Sep 23, 2026 contract
Sep 15, 2026 SEC ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (
Two ANIP insiders — a director and the SVP/General Counsel — sold a combined $107K in open-market transactions over a 4-
CLUSTER — Impact 2/10
Sep 15, 2026 Insider
Lalwani Nikhil sold 5,400 shares
PRESIDENT & CEO @ $71.00 ($383.4K)
Sep 14, 2026 Insider
Sep 1, 2026 SEC Cook Meredith sold 500 shares
SR. VP, GENERAL COUNSEL & SEC. @ $70.79 ($35.4K)
Two top ANIP executives—CEO Nikhil Lalwani and CFO Stephen Carey—collectively sold $609K in open-market shares within a
CLUSTER — Impact 3/10
ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026, and announced the res
8-K — Impact 2/10
Aug 24, 2026 Event
LITHOBID
WARNING Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | INITIATE | Perform | 52% |
| Aug 10, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 10, 2026 | Canaccord Genuity | MAINTAIN | Hold | 47% |
| Jul 17, 2026 | Canaccord Genuity | INITIATE | Hold | 47% |
| Jul 10, 2026 | Guggenheim | REITERATE | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Aug 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Jul 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Price targets
Where 9 covering analysts think ANIP trades over the next 12 months.
$105.78 +47.2% upside Strong Buy
Current$71.85 Low$85.00 Median$104.00 High$121.00 9 analysts
$85.00$121.00
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
18 SEC filing reports analyzed · 4 bullish, 1 bearish, 0 mixed, 13 neutral · avg impact 4.1/10.Plus 3 press releases.
NEUTRALCLUSTER2/10
Two ANIP insiders — a director and the SVP/General Counsel — sold a combined $107K in open-market tr
Sep 15, 2026
NEUTRALCLUSTER3/10
Two top ANIP executives—CEO Nikhil Lalwani and CFO Stephen Carey—collectively sold $609K in open-mar
Sep 1, 2026
NEUTRAL8-K2/10
ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026, a
Aug 24, 2026
NEUTRALCLUSTER3/10
Two ANIP insiders sold a combined $281K in open-market sales over a 7-day window following a strong
Aug 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 23, 2026
contract
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received fin
Sep 15, 2026
short_interest_report
Short Interest: ANIP down 26% to 2.5M shares
Settlement 2026-09-15 | Days to cover: 7.44 | ≈10.85% of shares outstanding (est.)
Aug 25, 2026
ftd
FTD: ANIP — 8,188 shares ($0.6M) failed to deliver
Settlement: 20260825, Price: $74.17, FTD Value: $607,303.96, ANI PHARMACEUTICALS INC
Aug 24, 2026
other
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –
Aug 24, 2026
FDA
LITHOBID
WARNING Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and acc
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.18 | $2.02–$2.33 | 6.9% | -0.8% | 0↑ 8↓ | $0.3B | 9 |
| Next Q | $2.83 | $2.57–$2.97 | 21.4% | -1.0% | 4↑ 4↓ | $0.3B | 9 |
| Current FY | $9.27 | $9.17–$9.37 | 17.5% | -0.2% | 2↑ 6↓ | $1.1B | 9 |
| Next FY | $10.40 | $9.46–$12.23 | 12.1% | -1.3% | 1↑ 7↓ | $1.2B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.181 | — |
| 7d ago | $2.165 | +0.016 |
| 30d ago | $2.199 | -0.018 |
| 60d ago | $2.508 | -0.327 |
| 90d ago | $2.502 | -0.321 |
Institutional ownership
Which big funds own ANIP (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.3B total value (15,262,503 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 26 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 2,958,646 | $244.9M | 19.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 838,224 | $69.4M | 5.5% | — |
| STATE STREET CORP | 831,647 | $68.9M | 5.4% | — |
| DIMENSIONAL FUND ADVISORS LP | 623,463 | $51.6M | 4.1% | — |
| AMERICAN CENTURY COMPANIES INC | 574,474 | $47.6M | 3.8% | DOUBLED +199.9% |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 562,016 | $46.5M | 3.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 536,407 | $44.4M | 3.5% | — |
| MILLENNIUM MANAGEMENT LLC | 507,207 | $42.0M | 3.3% | — |
| Nuveen, LLC | 415,024 | $34.4M | 2.7% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 407,281 | $33.7M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| AMERICAN CENTURY COMPANIES INC | DOUBLED | 191,576 | 574,474 | +199.9% | $47.6M |
| UBS Group AG | TRIM | 497,702 | 297,539 | -40.2% | $24.6M |
| Aberdeen Group plc | ADD | 206,123 | 271,760 | +31.8% | $22.5M |
| Rubric Capital Management LP | NEW | — | 258,131 | — | $21.4M |
| RAYMOND JAMES FINANCIAL INC | ADD | 80,620 | 131,270 | +62.8% | $10.9M |
| BARCLAYS PLC | ADD | 67,447 | 119,707 | +77.5% | $9.9M |
| Walleye Capital LLC | TRIM | 183,075 | 106,112 | -42.0% | $8.8M |
| Freestone Grove Partners LP | TRIM | 254,230 | 101,332 | -60.1% | $8.4M |
| Man Group plc | TRIM | 208,694 | 80,496 | -61.4% | $6.7M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 63,645 | 79,686 | +25.2% | $6.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
15 insiders, 50 transactions. Net -$10.7M — $0.00 bought, $10.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | CAREY STEPHEN P. | SVP & CFO | SELL | 2,850 | $73.00 | $208.1K |
| Sep 15, 2026 | Lalwani Nikhil | PRESIDENT & CEO | SELL | 5,400 | $71.00 | $383.4K |
| Sep 14, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $70.79 | $35.4K |
| Sep 11, 2026 | Thoma Jeanne | Director | SELL | 1,000 | $71.53 | $71.5K |
| Aug 31, 2026 | CAREY STEPHEN P. | SVP & CFO | SELL | 2,850 | $72.80 | $207.5K |
| Aug 25, 2026 | Lalwani Nikhil | PRESIDENT & CEO | SELL | 5,400 | $74.30 | $401.2K |
| Aug 19, 2026 | Gosebruch Henry O | Director | AWARD | 6,662 | — | — |
| Aug 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $75.48 | $37.7K |
| Aug 10, 2026 | Gutwerg Ori | SVP, GENERICS | SELL | 3,162 | $77.00 | $243.5K |
| Jul 29, 2026 | CAREY STEPHEN P. | SVP & CFO | SELL | 2,850 | $81.36 | $231.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ANIP.
Shares short
2,490,166
Settlement Sep 15, 2026
Change vs prior
-26.0%
Semi-monthly cycle
Days to cover
7.4
At avg daily volume
Of shares outstanding
≈10.8%
Estimate — not % of float
All ANIP filing & press-release reports (21)
- CLUSTER reportSep 15, 2026
- CLUSTER reportSep 1, 2026
- 8-K reportAug 24, 2026
- CLUSTER reportAug 14, 2026
- 8-K reportAug 7, 2026
- COURT-RULING reportJul 23, 2026
- PRESS-RELEASE reportJul 13, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 11, 2026
- 8-K reportMay 21, 2026
- CLUSTER reportMay 14, 2026
- 8-K reportMay 13, 2026
- 8-K reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportApr 24, 2026
- PRESS-RELEASE reportApr 8, 2026
- 8-K reportApr 7, 2026
- PRESS-RELEASE reportApr 7, 2026
- CLUSTER reportMar 13, 2026
- CLUSTER reportMar 10, 2026
- CLUSTER reportMar 10, 2026